Purinergic P2X 4 receptor
From MEpedia, a crowd-sourced encyclopedia of ME and CFS science and history
(Redirected from P2X4)
This article is a stub. |
Purinergic 2X 4 receptor or purinergic receptor P2 X, ligand-gated ion channel 4 or P2XR4 or P2X4 or P2RX4.[1]
Function[edit | edit source]
ME/CFS[edit | edit source]
Notable studies[edit | edit source]
- 2016, Gene expression factor analysis to differentiate pathways linked to fibromyalgia, chronic fatigue syndrome, and depression in a diverse patient sample[2] - (Full text)
- 2012, Genetics and Gene Expression Involving Stress and Distress Pathways in Fibromyalgia with and without Comorbid Chronic Fatigue Syndrome[3] (Full text)
- 2012, Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls[4] (Full text)
- 2012, Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome[5] (Full Text)
See also[edit | edit source]
- Transient receptor potential vanilloid receptor 1
- Purinergic P2X 5 receptor
- Acid sensing ion channel 3
- Post-exertional malaise
- Genetics of chronic fatigue syndrome
Learn more[edit | edit source]
- P2RX4 Protein | P2RX4 Antibody - Gene card
References[edit | edit source]
- ↑ "P2RX4 Protein | P2RX4 Antibody". Gene cards. Retrieved April 7, 2022.
- ↑ Iacob, Eli; Light, Alan R.; Donaldson, Gary W.; Okifuji, Akiko; Hughen, Ronald W.; White, Andrea T.; Light, Kathleen C. (January 2016). "Gene expression factor analysis to differentiate pathways linked to fibromyalgia, chronic fatigue syndrome, and depression in a diverse patient sample". Arthritis care & research. 68 (1): 132–140. doi:10.1002/acr.22639. ISSN 2151-464X. PMC 4684820. PMID 26097208.
- ↑ Light, KC; White, AT; Tadler, S; Iacob, E; Light, Alan R (2012). "Genetics and Gene Expression Involving Stress and Distress Pathways in Fibromyalgia with and without Comorbid Chronic Fatigue Syndrome". Pain Research and Treatment: 427869. doi:10.1155/2012/427869. PMC 3200121.
- ↑ White, AT; Light, AR; Hughen, RW; Vanhaitsma, TA; Light, KC (2012). "Differences in metabolite-detecting, adrenergic, and immune gene expression after moderate exercise in patients with chronic fatigue syndrome, patients with multiple sclerosis, and healthy controls". Psychosomatic Medicine. 74 (1): 46-54. doi:10.1097/PSY.0b013e31824152ed. PMC 3256093.
- ↑ Light, Alan R; Bateman, Lucinda; Jo, Daehyun; Hughen, Ronald W; Vanhaitsma, Timothy A; White, AT; Light, Kathleen (2012). "Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome". Journal of Internal Medicine. 271 (1): 64-81. doi:10.1111/j.1365-2796.2011.02405.x. PMC 3175315.